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“The heart muscle supplies the force which maintains the 
circulation. In the normal condition, the mechanism of the 
circulation is so adjusted that all parts combine to facilitate 
the work of the heart and to attain the object of the cir- 
culation. Any disturbance of that adjustment must at once 
entail more work upon the heart muscle, inasmuch as a 
departure from the normal means the embarrassment of the 
heart in maintaining normal arterial pressure. So long as 
the heart can overcome the impediment, and maintain the 
circulation in a normal manner, no symptoms are evoked, 
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but if the heart is no longer able to carry on the circulation 
efficiently, then certain phenomena at once arise, and these 
phenomena we call ‘symptoms of heart failure.’ ” 
Sir James MacKenzie 
Diseases of the Heart 
Oxford Universi~ Press, 1908 
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physician does not appear to investigate health in this way, 
but instead studies the health of man; or rather, of a par- 
ticular man. For he cares for each man as an individual.” 
Aristotle 
The Nicomachean Ethics 
Translated by P. B. Katz 
Introduction 
The 40th anniversary of the American College of Cardiology 
comes at a time of dramatic change in the management of 
congestive heart failure. Rapid developments in our under- 
standing of normal cardiac function and the pathogenesis of 
this common condition illustrate the growing impact of the 
basic sciences on clinical practice, and the way that concepts 
developed in the research laboratory come to influence 
strategies for the care of the patient (1). This article reviews 
current understanding of the regulation of cardiac function, 
and the way that clinical applications of these basic princi- 
ples are changing the treatment of patients with congestive 
heart failure. 
What is Heart Failure? 
A simple definition of heart failure is not possible as this 
condition arises from a variety of pathophysiologic pro- 
cesses; furthermore, the clinical manifestations of heart 
failure may differ considerably, even among patients in 
whom the condition arises from a single process like mitral 
stenosis (2). Most definitions focus on the clinical presenta- 
tion of the patient with heart failure and especially on the 
syndromes that appear when the failing heart becomes 
unable to meet the hemodynamic demands of the body. I 
believe, however, that this hemodynamic approach to the 
definition of heart failure perpetuates an outdated tradition 
that, by emphasizing the circulatory impairment, inade- 
quately recognizes important cellular changes in the hyper- 
trophied and failing heart. For these myocardial cellular 
abnormalities, rather than the disordered circulation, are 
largely responsible for the poor prognosis in these patients, 
about 50% of whom die within 5 years after an initial 
diagnosis of heart failure (3). Definitions of heart failure that 
focus on disorders of the circulation, which in fact represent 
not the cause but the consequences of an impaired ability of 
the heart to meet the demands of the body, are therefore 
incomplete. It can even be argued that to define heart failure 
in terms of abnormal hemodynamics inappropriately diverts 
attention from important cellular abnormalities that develop 
in the hypertrophied heart. Such definitions, by not recog- 
nizing a cardiomyopathy of overload as one of the major 
causes of clinical deterioration and death, can misdirect 
therapeutic strategies for this common and deadly condition. 
MacKenzie’s definition of heart failure, which is repro- 
duced at the beginning of this article, highlights the interplay 
between the heart and circulation. MacKenzie clearly un- 
Table 1. Three Mechanisms That Regulate the Work of the Heart 
Regulation by changing end-diastolic fiber length (Starling’s law of the 
heart). 
Beat to beat responses to altered hemodynamics; adjustment of 
cardiac output to changing preload and afterload, and equalization of 
the outputs of the two ventricles. 
Regulation by biochemical changes within the myocardial cell 
(excitation-concentration coupling and myocardial contractility). 
Short-term responses of the heart to physiologic and pharmacologic 
interventions; e.g., neurotransmitters and cardiac drugs. 
Regulation by altered gene expression (molecular biology). 
Long-term adaptation of myocardial cells to the functional 
heterogeneity of the heart, and to chronic changes in cardiac loading, 
endocrinopathies and aging. 
derstood the primary role of the myocardial abnormalities in 
heart failure when he wrote: 
“The more I study the symptoms of heart failure, and the 
more I reflect on the part played by the heart muscle, the 
more convinced I am that the explanation of heart failure 
can be summed up in the general statement that heart 
failure is due to the exhaustion of the reserve force of the 
heart muscle . . .” (4). 
Although the “reserve force of the heart muscle” could 
not be understood in terms of the science of 1908, research 
over the past 81 years has clarified the mechanisms that 
control the contractile processes in the heart. Today, this 
knowledge provides the foundation for new therapeutic 
strategies that, when individualized to treat specific abnor- 
malities present in each patient with heart. failure, both 
relieve symptoms and improve prognosis. 
Three Mechanisms That Regulate the Work 
of the Heart 
Current approaches to the therapy of heart failure are 
based on the new understanding that the work of the heart is 
regulated by at least three fundamentally different mecha- 
nisms (Table 1). Although each plays a unique role in 
adjusting the performance of the heart to the needs of the 
body, it is their interplay that defines cardiac and circulatory 
regulation in health and disease (5). 
Forty years ago, only the role of changing end-diastolic 
jiber length (Starling’s law of the heart) was understood; this 
mechanism operates at the organ level to adjust the output of 
the heart to changing preload and afterload on a beat to beat 
basis. Changes in myocardial contractility, which regulate 
cardiac performance over a slower time course largely by 
altering the calcium fluxes involved in excitation-contraction 
coupling, came to be understood over the past 25 years. This 
biochemical mechanism allows individual myocardial cells 
to respond to humoral stimuli, such as the sympathetic 
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Table 2. Changing Strategies in the Management of Congestive Heart Failure 
Phase I (1948 to 1968): Digitalis and Diuretics 
Cardiac glycosides 
Diuretics 
Phase II (1968 to 1978): Vasodilators 
Alpha-adrenergic blockers 
Nitrates 
Arteriolar dilators 
Calcium channel blockers 
Phase III (1978 to 1988): Inotropic stimulation 
Beta-adrenergic agonists 
Calcium sensitizing agents 
Phosphodiesterase inhibitors 
Phase IV (1988-J: Preserve the failing heart 
Converting enzyme inhibitors 
Beta-adrenergic blockers 
Phase V (‘71: Correct the myocardial abnormality 
17 
Increase inotropy; reduce dromotropy in atrial fibrillation 
Reduce preload 
Reduce preload and afterload 
Reduce preload 
Reduce afterload 
Reduce afterload 
increase inotropy and lusitropy 
Increase inotropy 
Increase inotropy and lusitropy 
Reduce preload and afterload 
Reduce inotropic stimulation 
Reduce inotropy 
Modtfy synthesis of abnormal gene products 
Data are approximations 
neurotransmitters released during exercise. Regulation by 
variable gene expression. the third of these mechanisms, 
brings about changes in myocardial protein composition that 
alter cardiac function over an even slower time course; for 
example, in the response to chronically altered cardiovascu- 
lar function as occurs in endocrinopathies, aging and chronic 
hemodynamic overloading (6-8). Regulation by variable 
gene expression also makes possible a remarkable cellular 
and molecular heterogeneity that underlies the essential 
functional homogeneity of the heart as an organ (5,9). 
The evolution of our understanding of the regulatory 
mechanisms listed in Table I has contributed to the changing 
management of congestive heart failure summarized in Table 
2. Starling’s law of the heart and alterations in myocardial 
contractility, which until recently dominated thinking in 
cardiology, had initially determined strategy for managing 
patients with congestive heart failure. However, it is now 
apparent that optimal therapy for these patients must also be 
based on knowledge of the altered composition and behavior 
of the overloaded cells of the failing heart. Thus, to treat the 
patient with congestive heart failure, the physician must 
understand the interplay between all three of the regulatory 
mechanisms that determine the state of the circulation, the 
heart and the individual cells of the myocardium. 
Strategies for the Management of Congestive 
Heart Failure. Phase I: Digitalis 
and Diuretics 
Forty years ago; treatment of heart failure focused largely 
on two groups of drugs, the cardiac glycosides and mercurial 
diuretics. The former had been in use for >I50 years, since 
Withering (10) had identified the foxglove as the active 
ingredient in a secret family recipe used to treat dropsy. 
Calomel (mercurous chloride), like digitalis, had been rec- 
ognized to induce diuresis in patients with dropsy since the 
latter half of the 18th century; however, the toxicity and 
unpredictable effects of this inorganic mercurial precluded 
its routine use. It was not until 1920 that the diuretic effect of 
the organic mercurials was discovered accidentally in a 
patient who was receiving one of these compounds for the 
treatment of syphilitic aortitis (11). Supplemented by the 
weaker diuretic actions of the xanthines, the organic mercu- 
rials had joined digitalis as standard therapy for heart failure 
when the American College of Cardiology was founded in 
1949. 
Strategies for the Management of Congestive 
Heart Failure. Phase II: Vasodilators 
Heart Failure as a Hemodynamic Abnormality 
It is possible to trace the beginnings of the second phase 
in the evolution of our strategy for the management of heart 
failure to the introduction of cardiac catheterization into 
clinical medicine shortly after World War II. This Nobel 
prize-winning advance made it possible to evaluate heart 
failure in terms of basic hemodynamic principles and overall 
cardiac energetics, topics once viewed as only of theoretical 
interest. Measurements of cardiac output and pressures in 
the cardiac catheterization laboratory, and the development 
of flow-directed catheters in the coronary care unit, made it 
possible to characterize hemodynamic abnormalities in pa- 
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tients with both chronic and acute heart failure. This ap- 
proach provided the basis for the second phase in the 
evolving strategy for managing heart failure (Table 2) when 
measurements of peripheral resistance in patients with heart 
failure made it possible to understand how vasoconstriction, 
long known to be compensatory in acute heart failure (12), 
contributed to the clinical disability in patients with chronic 
heart failure (13). Recognition of the detrimental effects of 
vasoconstriction in turn provided a foundation for later 
demonstrations that afterload reduction could relieve symp- 
toms (14) and prolong life (15) in patients with heart failure. 
Today, of course, vasodilator therapy has joined digitalis 
and diuretics as standard therapy for this condition. 
Strategies for the Management of Congestive 
Heart Failure. Phase III: 
Inotropic Stimulation 
Heart Failure as an Abnormality of Myocardial 
Cell Biochemistry: Depressed Contractility in 
the Failing Heart 
At the same time that improved understanding of the 
interplay between the heart and circulation refined strategies 
for the management of heart failure through manipulation of 
the peripheral vasculature, it was becoming apparent that 
the cardiac abnormality in patients with heart failure in- 
volved more than abnormal cardiac metabolism (16-18) and 
the descending limb of the Starling curve (19). Yet as 
recently as the mid 1960s the importance, and indeed the 
existence, of cardiac muscle abnormalities in the patient 
with heart failure had not been established, and myocardial 
contractility had not been shown to be depressed in these 
patients. Thus, in summarizing the deliberations of a distin- 
guished group of cardiologists and cardiovascular physiolo- 
gists who examined this question in 1964, I was forced to 
write: “, . . the basic question: ‘Is the failure of chronically 
overloaded hearts the result of abnormalities within the 
cardiac fiber?’ remains unanswered . . .” (20). This question 
was answered only when myocardial contractility (MacKen- 
zie’s “reserve force”), came to be understood in biochemi- 
cal and biophysical terms (Table 1). Characterization of the 
state of the myocardium in patients with congestive heart 
failure became possible when the work of the heart was 
recognized to be regulated by changes in myocardial cell 
biochemistry, which were expressed clinically as abnormal- 
ities in myocardial contractility. 
Our present understanding of the role of depressed myo- 
cardial contractility in the pathogenesis of heart failure is 
based on two lines of research, both of which were stimu- 
lated by the observation that factors other than end-diastolic 
fiber length determined the performance of the heart (5,21). 
Recognition that changing properties of individual myocar- 
dial cells played a major role in controlling the work of the 
heart (Table 2) stimulated efforts to characterize the mechan- 
ical behavior of the heart in terms of skeletal muscle me- 
chanics (22,23). At the same time, rapid progress in our 
understanding of the biochemical and biophysical processes 
that regulate myocardial contractility made clear the central 
role of Ca2+ in cardiac excitation-contraction coupling (24). 
Application of this new understanding to evaluate myocar- 
dial function in humans led to the demonstration that myo- 
cardial contractility was, in fact, depressed in patients with 
heart failure (25). 
The Search for the Ideal Inotropic Agent 
A seemingly obvious corollary to the depressed myocar- 
dial contractility in patients with heart failure, which until 
recently dominated strategy for management of this syn- 
drome, was that the condition of these patients would be 
improved by increasing contractility in the failing heart. The 
conclusion that more powerful inotropic stimulation would 
be beneficial to these patients gained support from clinical 
experience in the coronary care unit, where temporary 
inotropic support of the failing left ventricle was of clear 
value in treating the acute heart failure that followed massive 
myocardial infarction. The view that survival could be 
similarly improved by increasing myocardial contractility in 
chronic congestive heart failure stimulated a search for 
improved means to increase contractility in these patients. 
Cardiac glycosides. Forty years ago, the cardiac glyco- 
sides were the only useful positive inotropic agent for the 
treatment of heart failure. I suspect, however, that the 
benefit of these agents was due, in large part, to their ability 
to slow ventricular rate in atria1 fibrillation. Such a view had 
been expressed by two of the giants of British cardiology. Sir 
James MacKenzie wrote in 1918: 
“In searching the records in literature for the evidence of the 
good effects of digitalis, I feel fairly certain that it is in 
patients with auricular fibrillation, particularly when it is 
subsequent to rheumatic fever, that the extraordinarily 
good results have been obtained. If one reads carefully the 
records given by Withering in the first valuable account of 
digitalis in 1785, though he used it as a diuretic, yet he 
noted its good effects in heart cases; and several of his 
successful cases had undoubtedly auricular fibrillation” 
(26). 
Twenty years later, Sir Thomas Lewis wrote: “It is to their 
striking effect in cases of auricular fibrillation that drugs of 
the digitalis group almost conclusively owe their well- 
founded reputation” (27). Even in the 1940s rheumatic heart 
disease was the leading cause of heart failure, affecting about 
2% of the population (28), and atria1 fibrillation was found in 
about 40% of patients with mitral stenosis (29). 
Regardless of the basis for their wide acceptance, the 
cardiac glycosides were given as a matter of course to 
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virtually every patient who appeared to be suffering from 
congestive heart failure. However, the low therapeutic/toxic 
ratio of the cardiac glycosides had, for years, stimulated 
unsuccessful efforts to identify a safer drug of this class. This 
search ended only recently when it was realized that the 
therapeutic and toxic effects of the cardiac glycosides both 
arose from the same molecular interaction of these drugs 
with the cardiac cell, which by inhibiting the sodium pump 
(30), increases intracellular sodium concentration and so 
promotes calcium entry by Na/Ca exchange (31). 
Early inotropic agents. Although the benefit derived from 
the positive inotropic actions of the catecholamines in the 
short-term management of patients with acute myocardial 
infarction suggested their possible usefulness in chronic 
congestive heart failure, most inotropic drugs available 40 
years ago were poorly suited for long-term administration. 
The sympathomimetic amines of that time had chronotropic 
and arrhythmogenic side effects that precluded their routine 
use in the management of chronic congestive heart failure, 
whereas phosphodiesterase inhibitors like aminophylline 
were short-acting and sometimes caused arrhythmia and 
sudden death. 
Paired pulse stimulation. The inotropic effect of postex- 
trasystolic potentiation enjoyed a brief moment in the spot- 
light of clinical cardiology over 20 years ago (32). This now 
almost forgotten inotropic therapy attempted to use the 
marked potentiation of the contraction after a premature 
systole, a manifestation of the positive (Bowditch) staircase, 
to treat heart failure. Although paired pulse stimulation was 
once viewed as having clinical potential in the management 
of patients with heart failure, the risk of inducing arrhyth- 
mias and interference with ventricular filling by the prema- 
ture systoles was quickly recognized and this hazardous 
approach to therapy was abandoned. 
New inotropic agents. The search for new inotropic drugs 
was facilitated by rapid advances in our understanding of the 
ability of cyclic adenosine monophosphate (AMP), the sec- 
ond messenger that mediates the cellular effects of sympa- 
thomimetic amines, to modify the Ca’+ fluxes responsible 
for cardiac excitation-contraction coupling. it now appears 
that, with the notable exception of the cardiac glycosides. 
most inotropic agents that have been examined clinically act 
by increasing the rate of cyclic AMP production or decreas- 
ing the rate of breakdown of this second messenger (33). 
Whereas the bipyridines, introduced a decade ago as 
“novel” inotropic drugs, are now generally accepted to be 
phosphodiesterase inhibitors, another class of new agents, 
the imidazopyridines, increase the Ca’+ sensitivity of the 
contractile proteins (34). Clinical applications of drugs that 
modify various ion channels in the cardiac sarcolemma are 
still lo be found: examples are agents that prolong sodium 
channel opening. and so promote calcium entry through 
exchange of the increased cellular Na+ with extracellular 
Ca*+ by way of NaiCa exchange (35). Other inotropic drugs 
delay the closing of the potassium channels that cause 
membrane repolarization; the resulting increase in action 
potential duration prolongs calcium channel opening and so 
increases cellular Ca’+. Although these mechanisms are of 
promise in the development of truly novel inotropic drugs, 
new knowledge of the pathophysiology of heart failure is 
bringing this phase in the management of congestive heart 
failure to a close. 
Lirnitations on the Use of Inotropic Agents for 
the Management of Congestive Heart Failure 
Major conceptual advances in our understanding of the 
cardiac abnormalities in patients with congestive heart fail- 
ure are now shifting therapeutic strategies away from efforts 
to increase contractility. This redirection of the goals of 
therapy is due in part to the recognition of the role of 
relaxation abnormalities in these patients and to the realiza- 
tion that relaxation is especially sensitive to an imbalance 
between energy production and energy utilization in the 
myocardium. 
Importance of relaxation (lusitropic) abnormalities. Em- 
phasis on inotropic abnormalities during the “phase of 
inotropic stimulation” (Table 2) reflected the widely held 
view that heart failure was due entirely. or at least largely, to 
impaired ability of the heart to contract. This focus on 
systolic abnormalities was, in no small measure, a reflection 
of the utilization of intraventricular pressure measurements 
as the reference standard for evaluating ventricular function. 
As the indexes most easily derived from pressure curves 
occur during the isovolumic phase of systole, such estimates 
of myocardial contractility as positive first derivative of left 
venrricular pressure (tdP/dt), V,,,, and V,, once domi- 
nated the assessment of cardiac dysfunction in patients with 
heart failure. Because of difficulties in evaluating relaxation 
by the use of pressure-derived indexes based on catheteriza- 
tion data. it was not until the introduction of noninvasive 
methods for the study of ventricular wall motion (echocar- 
diography) and volume changes (nuclear cardiology) that 
simple and accurate evaluations of diastolic function became 
feasible in the failing human ventricle (36). Over the past 
decade, these new clinical methods revealed that relaxation 
abnormalities played a much greater role in the pathogenesis 
of heart failure than had previously been suspected (37). 
Elnergy is required for the heart to relax. Recognition of 
the importance of relaxation abnormalities in the pathogen- 
esis of congestive heart failure highlighted the clinical signif- 
icance of the fact that relaxation, like contraction, is an 
energy-requiring process (38). This raised the possibility that 
the lusitropic abnormalities commonly encountered in these 
patients might be due to a lack of energy in the overloaded 
myocardium, and so added to earlier concerns (39) that 
inotropic stimulation, by increasing energy expenditure in 
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the failing heart, might represent an inappropriate strategy 
for routine therapy of congestive heart failure (40,41). 
Is the failing heart an energy-starved heart? In most 
patients with heart failure, whether due to hemodynamic 
overloading, loss of functional myocardial tissue or a valve 
abnormality, the work of the active myocardial cells, and so 
their expenditure of energy, are increased on a long-term 
basis. However, there is abundant evidence, albeit mostly 
indirect, that the cells of the hypertrophied and failing heart 
are unable to generate sufficient energy to provide for this 
increased rate of energy expenditure; as a result, the failing 
heart is likely to be in an energy-starved state (42). 
A number of changes that occur in the failing heart can 
impair the ability of the hypertrophied myocardial cells to 
meet their increased energy needs. Intercapillary distance is 
increased (43) and there is a decreased number of transverse 
capillary profiles per square millimeter (44); both would 
increase the distance required for the diffusion of substrates, 
notably oxygen, to the cells of the hypertrophied heart. A 
resulting predisposition to a state of energy deficiency would 
be especially severe in the relatively underperfused suben- 
docardial regions of the hypertrophied ventricle (45). 
Changes in the composition of the cells in the chronically 
overloaded myocardium represent another possible cause 
for an energy-starved state in the failing heart. Several 
experimental studies (44,46,47) have shown that the fraction 
of cell volume occupied by myofibrils in the hypertrophied 
heart is increased, whereas mitochondrial mass decreases; 
changes that could exacerbate an energy deficit by increas- 
ing the number of adenosine triphosphate (ATP)-consuming 
myofibrils that must be supported by each ATP-generating 
mitochondrion. 
Myocardial high energy phosphate content has been 
found to be decreased in the pressure-overloaded left (48) 
and right (49) ventricles in animal models of heart failure. 
Cardiac biopsies in patients with congestive heart failure 
have also shown that reduced content of high energy phos- 
phate compounds (50) correlates with the extent of impair- 
ment of both contraction and relaxation (5 1). These data are 
consistent with the view that a chronic myocardial energy 
deficit contributes to the deterioration in patients with 
chronic congestive heart failure. 
Strategies for the Management of Congestive 
Heart Failure. Phase IV: Preserve the 
Failing Heart 
Much like the once prevalent “senescence” theory of 
atherosclerosis as an inevitable consequence of the aging 
process (52), the progressive deterioration in patients with 
congestive heart failure was, until a few years ago, thought 
to be unavoidable and untreatable. This fatalistic view was 
heightened by the fact that heart failure often results from 
clinical conditions, such as some of the cardiomyopathies, 
that are themselves progressive. As recently as the mid 
1980s therapy of severe congestive heart failure was be- 
lieved to have little likelihood of improving the poor prog- 
nosis in these patients (53). 
This hopeless view of congestive heart failure was dra- 
matically reversed by recent demonstrations that medical 
therapy could, in fact, significantly prolong life (15,54) and 
slow cardiac deterioration (55) in these patients. This real- 
ization has stimulated a new emphasis on efforts to preserve 
the failing heart and added significance to studies of the 
molecular biology of the overloaded myocardium. 
Spontaneous Deterioration of the 
Hypertrophied Heart 
Almost a century ago, Osler (56) recognized that the 
clinical state in patients with a hemodynamically overloaded 
heart follows a predictable course. The first response to a 
lesion like acute aortic regurgitation is a period of “devel- 
opment,” during which the myocardium hypertrophies to 
meet the increased load. This leads into a stage of “compen- 
sation,” in which acute heart failure caused by the increased 
load is alleviated as hypertrophy distributes the increased 
load among a larger number of cardiac fibers. Osler recog- 
nized, however, that the hypertrophied heart tends to un- 
dergo spontaneous, progressive deterioration in a final stage 
of “broken compensation.” 
The cardiomyopathy of overload. The modern era of 
understanding the causes of deterioration of the overloaded 
heart began with the monumental work of Meerson (57), who 
found that experimental aortic coarctation causes the myo- 
cardium to undergo a sequence of structural and biochemical 
changes that lead to fibrosis and cell death (Table 3). 
Hypertrophy, which begins during the initial phase in this 
sequence (analogous to Osler’s “development”), represents 
a beneficial response as the increased mass of heart muscle 
distributes the overload among a greater number of sarco- 
meres (analogous to Osler’s “compensation”). However, 
this response carries with it a heavy price; much like Faust’s 
bargain with the devil, a brief period of pleasure is followed 
by an eternity of pain! This occurs because the cells of the 
hypertrophied heart are not normal and, in the face of 
sustained overloading, deteriorate and die (analogous to 
Osler’s “broken compensation”), thereby initiating a vi- 
cious cycle by further increasing the load on the surviving 
cells (Fig. 1). The response of the heart in patients with 
congestive heart failure therefore resembles that of the 
circulation described by Harris (12), where mechanisms like 
vasoconstriction and sodium retention are compensatory for 
the short term, but come to have deleterious long-term 
effects. It is clear that, as stated over 20 years ago: “the 
failing heart is not simply an enlarged version of the normal 
heart” (58). On the contrary, the cells of the hypertrophied 
heart undergo a progressive deterioration that can be viewed 
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Table 3. Three Stages in the Response to a Sudden Hemodynamic Overload 
Stage I (days): Transient breakdown 
Circulatory: Acute heart failure; pulmonary congestion, low output 
Cardiac: Acute left ventricular dilation. early hypertrophy 
Myocardial: Increased content of mitochondria relative to myofibrils 
Stage 2 (weeks): Stable hyperfunction 
Circulatory: Decreased pulmonary congestion and improved cardiac output 
Cardiac: Established hypertrophy 
Myocardial: Increased content of myofibrils relative to mitochondria 
Stage 3 (months): Exhaustion and progressive cardiosclerosis 
Circulatory: Progressive left ventricular failure 
Cardiac: Further hypertrophy with progressive fibrosis 
Myocardial: Cell death 
This table is based on experimental studies of the response of the heart to aortic constriction described by 
Meerson (571. 
as a “cardiomyopathy of overload,” which may become a 
major determinant of the downhill course in patients with 
this condition. 
Possible role for energy starvation. A clue to the mecha- 
nisms responsible for the progressive deterioration of the 
overloaded myocardium is found in the “stone heart 
syndrome.” This form of ischemic contracture was de- 
scribed by Cooley et al. (59) in patients with severe left 
ventricular hypertrophy who underwent open heart surgery 
with inadequate cardioplegia. This syndrome, which appears 
to result from high energy phosphate depletion that occurs 
when the severely overloaded heart become ischemic (60), 
may represent a model for the slower myocardial cell dete- 
rioration seen when patients with chronic congestive heart 
failure are treated medically. 
A word of caution is in order, however. If the past is any 
guide to the future (1,5,21), the final answer to the important 
question of what causes the progressive deterioration in the 
overloaded heart is likely to be far more complex than can be 
imagined today. For example, it is by no means impossible 
that accelerated senescence accompanies the hypertrophy 
that develops in the cells of the overloaded heart. 
Figure 1. By increasing the number of contractile units, and so 
reducing the loading on each sarcomere of the overloaded heart (-), 
hypertrophy is beneficial. However, hypertrophy also initiates myo- 
cardial changes that lead ultimately to cell death. As a result, 
hypertrophy perpetuates a vicious cycle that, by reducing the 
number of contractile units, increases the load on each of the 
surviving cells (t 1. 
Composition 
Morphologic changes in the hypertrophied heart. Com- 
plex morphologic abnormalities in hypertrophied and failing 
hearts have long been recognized. Using light microscopy, 
Linzbach (61) observed that the myocardial cells are uni- 
formly and moderately enlarged in the mildly hypertrophied 
heart (“concentric hypertrophy”), whereas he attributed 
thinning of the wall of the heart in more severe heart failure 
(“eccentric hypertrophy”) to weakening of connective tis- 
sue and destruction of myofibers. It is now apparent that 
changes in the extracellular matrix of the hypertrophied 
heart reflect very complex processes; for example, fibrosis 
involves not only changes in the amount of collagen, but also 
the appearance of different types of collagen during the 
different phases of the response to overload (62). Evidence 
that chronic overloading of the heart leads to changes in 
cardiac composition (44,46,47) and alterations in the number 
of beta-adrenergic receptors (63) provides further examples 
of important changes in the composition of the hypertro- 
phied and failing heart. 
Heart Failure as an Abnormality of Gene 
Expression in the Myocardium 
Molecular changes now recognized to occur in the indi- 
vidual proteins of the hypertrophied and failing heart have 
functional consequences that can be both compensatory and 
deleterious in the patient with congestive heart failure. 
Alpert and Gordon (64) first suggested such molecular 
changes when they reported that cardiac myosin adenosine 
triphosphate (ATPase) activity is depressed in congestive 
heart failure. Subsequent demonstrations that cardiac myo- 
sin ATPase activity changes not only in response to chronic 
overload, but also in aging and the endocrinopathies (65), 
suggested that altered protein structure represents a “tonic” 
mechanism (6) by which myocardial function becomes 
adapted to long-term circulatory changes (Table I). These 
early concepts have recently been incorporated into the 
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fast-moving fields of “molecular biology,” which are dem- 
onstrating a hitherto unimagined degree of molecular heter- 
ogeneity in the proteins of the myocardium (9). 
Variability of gene expression in the heart. Growing 
knowledge of the mechanisms responsible for the remark- 
able variability of gene expression in the heart has defined a 
key role for changes in the cardiac proteins in determining 
the myocardial response in patients with heart failure. Al- 
though this field is still in its infancy, characterization of 
cardiac myosin, the major protein of the thick filament that is 
readily isolated in pure form and in large amounts from heart 
muscle, illustrates a number of important functional and 
biochemical features of these changes in gene expression (66- 
68). These focus on the myosin “heavy chains,” which 
determine the rate of energy liberation by myosin both in vitro 
(ATPase activity) and in vivo (muscle shortening velocity). 
The myosin heavy chains, which are encoded by several 
gene families, are expressed differently among different 
muscles and at different times in a single muscle during 
ontogeny (67). In the adult heart, chronic hemodynamic 
overloading and heart failure are among the most important 
causes of altered cardiac myosin gene expression (66,69-75). 
This is readily apparent in the rat ventricle, which can 
express several myosin heavy chain isoforms; the V, (alpha) 
myosin heavy chain determines a high myosin ATPase 
activity and rapid shortening velocity, whereas the V, (beta) 
myosin heavy chain determines low myosin ATPase activity 
and slow shortening velocity. In the overloaded, hypertro- 
phied myocardium, the preferential synthesis of the messen- 
ger ribonucleic acid that encodes the low ATPase V, heavy 
chain (74) leads to the replacement of fast myosin with slow 
myosin, which decreases the rate of cross-bridge cycling and 
so reduces myocardial contractility. However, at the same 
time that this alteration in gene expression has a negative 
inotropic effect, mechanical efficiency is increased (8,39). 
Thus, one result of the changing expression of different 
myosin heavy chain genes in hypertrophy is an energy- 
sparing effect that facilitates the adaptation of the heart to 
the chronically increased hemodynamic load. Although the 
human ventricle is now recognized to contain only one 
myosin heavy chain isoform, a similar change in myosin 
gene expression has been observed in overloaded human 
atria, where a decreased proportion of fast (alpha) atria1 
myosin heavy chain parallels the extent of left atria1 enlarge- 
ment (76). 
Expression of different protein isoforms in the hypertro- 
phied heart has also been reported for two proteins of the 
thin filament; actin (77,78) and tropomyosin (78). This re- 
sponse represents more than a simple “up-regulation” of 
sarcomere synthesis, as is apparent from evidence that 
expression of altered myosin and actin isoforms follows 
different time courses (77,78). 
Isoform changes in the hypertrophied heart have also 
been reported for lactate dehydrogenase (79), creatine ki- 
nase (80,81) and the sarcolemmal sodium pump (82). That 
this list is incomplete is evidenced by major functional 
changes in the failing heart that have not yet been explained 
at a molecular level. Among the latter is the severely 
impaired relaxation seen when heart muscle from patients 
with dilated or hypertrophic cardiomyopathy is studied in 
vitro (83). Although this lusitropic abnormality may be due 
in part to a deficit in chemical energy, the mechanism 
appears to be more complex and may involve increased 
sensitivity of the energy-dependent reactions that relax the 
heart to as yet poorly understood energetic abnormalities in 
the hypertrophied myocardium (84). 
Therapeutic implications of excessive energy demands by 
the hypertrophied heart. Demonstration that changes in the 
synthesis of specific myocardial proteins reduce contractility 
in the hypertrophied heart raises fascinating questions as to 
whether these changes are compensatory or deleterious. I 
believe that they are both (39). Insofar as the changes in 
myosin heavy chain isoforms synthesized by the overloaded 
heart reduce myocardial contractility, the alterations in gene 
expression are detrimental to pumping by the failing heart. 
This view has, in the past, provided a rationale for efforts to 
increase myocardial contractility in patients with heart fail- 
ure. At the same time, however, the important energy- 
sparing effect of depressed contractility could preserve myo- 
cardial cell viability in an energy-starved heart and so, like 
afterload reduction, might prolong survival in patients with 
congestive heart failure. 
A logical corollary to the interpretation that depression of 
contractility in the overloaded heart has a potentially bene- 
ficial energy-sparing effect is that negative inotropic agents 
could be of value in preserving cell viability in the chroni- 
cally overloaded heart (39). Such an interpretation is sup- 
ported by the ability of vasodilators to prolong survival and 
preserve myocardial function in patients with congestive 
heart failure (15,54,55), a beneficial effect that may be due, at 
least in part, to a reduced rate of energy utilization by the 
overloaded cells of the failing heart (42). The ability of 
negative inotropic drugs to produce a similar energy-sparing 
effect may explain the results of several clinical trials (85-90) 
that indicate that beta-adrenergic blocker therapy can pro- 
long survival and slow deterioration in patients with heart 
failure. Although these observations in no way deny the 
hazards of negative inotropic therapy in heart failure, espe- 
cially when it is acute as in cardiogenic shock, they offer 
hope that means are at hand to alter further the bleak 
prognosis in patients with chronic congestive heart failure. 
Strategies for the Management of Congestive 
Heart Failure. Phase V: Correct the 
Myocardial Abnormality 
Should efforts be made to modify the evolution of hyper- 
trophy in the failing heart? We have seen how the remark- 
able plasticity in cellular composition of the myocardium 
gives rise to important functional changes in the hypertro- 
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process itself (Fig. 1). Although attempts to modify deteri- 
mental changes in gene expression in the patient with 
congestive heart failure are not yet feasible, the likely 
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efforts to formulate new strategies to modify gene expression 
in the failing heart. 
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Conclusions 
As it is essential to understand the past before attempting 
to predict the future, this article has focused largely on the 
history of strategies for the therapy of congestive heart 
failure. Three important points can be drawn from this 
historic survey. The first, apparent when Table 2 is exam- 
ined in light of Table 1, is that new clinical strategies, 
although often initiated by thoughtful and careful clinical 
observation, become established when they find support in 
concepts derived from basic research. I do not mean to 
imply that innovations in clinical practice depend on basic 
research; more often, it is the other way around in that novel 
observations in patients frequently direct basic research to 
important clinical problems. In fact, new ideas in medicine 
find clinical application most rapidly when basic and clinical 
science advance together. 
The second point of this review is that the pace of 
scientific advance is accelerating (Table 2). It is no exagger- 
ation that we have learned more of value about the therapy 
of heart failure in the past 10 years than had been learned 
previously since the dawn of time (91). 
Finally, the history of science teaches us that important 
advances come from unexpected directions. This caveat 
notwithstanding, it seems safe to predict that better under- 
standing of regulation of gene expression, coupled with new 
knowledge about the biochemistry of the hypertrophied and 
failing heart, will provide means by which myocardial com- 
position can be altered so as to benefit the patient with 
congestive heart failure. Such a capability could allow the 
fifth of the strategies set forth in Table 2 to be achieved; but 
how to restore normal structure and function in the myocar- 
dium of the patient with congestive heart failure is, of 
course, a question for future research. 
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